NPPA and hyperparathyroidism: Despite an improvement of hyperparathyroidism, FGF23 did not change renal function and pathology and cardiac mRNA expression of pro-hypertrophic markers including skeletal muscle α-actin, myosin heavy chain (MHC) and atrial natriuretic peptide (ANP).